

## CEMIL BILIR, M.D.



**Date of Birth:** May 22/ 1980

**Place of Birth:** Gebze-Kocaeli, Turkey.

**Address:** 32 Evler mh 822 sokak, 15-D5  
Serdivan-SAKARYA,TURKEY.  
54100

**Phone:** +90(535)253-5124  
Cellular phone: +90 (505)201-4666

**E-mail:** cebilir@yahoo.com

**Work:** Sakarya University, School of Medicine

Work Adress: Sakarya Universitesi Tıp Fakültesi Dekanlığı,  
Korucuk Mahallesi Konuralp Bulvarı No:81/1  
Korucuk Kampüsü, Adapazarı/Sakarya

### Personal Statement

I am a Medical Oncologist since 2013 and have an academic position as the head of a department in a University Hospital for five years. My clinical specialties are urologic and gynecologic cancers. I enrolled more than 20 phase 2 and 3 trials as a PI / subI with many companies (eg:MSD; Astrazenaca, Roche, Novartis, Takeda.), which most of the trials were about immunotherapies and new targeted therapies. Between 2016 and 2017, for a year, I had an opportunity to join Prof. Torchlins lab. at the Northeastern University, Center For Pharmaceutical Biotechnology And Nanomedicine- Boston-MA. I worked between the period of 2015-2021 at Sakarya University.

### EDUCATION

#### Date School Diploma or Degree

1991-1998	Gebze Anadolu Lisesi (English High school) Middle-High school Diploma
1998-2004	Istanbul University School of Medicine Doctor of Medicine (6 years Medical School)
2005-2009	Duzce University School of Medicine Resident Doctor in Internal Medicine (4 years residency)
2009-2010	Cleveland Clinic Observership in MICU and Gastroenterology,
2009-2010	Istanbul University School of Medicine Rheumatology and Hematology residency
2010-2013	Bulent Ecevit University School of Medicine, Medical Oncology Fellowship (3 years Fellowship)

## EXPERIENCE

### Date Institution Location Position

2005- Duzce University School of Medicine Resident Doctor in Internal Medicine  
2009- Istanbul University School of Medicine Rheumatology Rotation  
2009- Istanbul University School of Medicine Hematology Rotation  
2009 May- August Cleveland Clinic Foundation-OH(USA) MICU (Observership Rotation), Cleveland Clinic Foundation-OH(USA) Gastroentero-Hepatology (OR)  
2010 Internal Medicine Compulsory service of Health of Ministry  
2010-2013 Medical Oncology Fellowship program  
2014 Medical Oncology Compulsory service of Health of Ministry, Rize Turkey  
2015 Associate Professor of Medicine (Internal Medicine and Medical Oncology), Sakarya University, Turkey  
6.2016-6.2017 **Northeastern University-Boston,MA- Center for pharmaceutical biotechnology and nanomedicine, Drug Delivery**; I worked as a visiting Professor and experienced about drug delivery with liposomes, studied with IDO inhibitors.  
2017- Head of Medical Oncology department AT Sakarya University (Internal Medicine and Medical Oncology), Sakarya University, Turkey  
2020-August. Professor of Medicine at Sakarya University  
2020 Jan- Phd student- Chemistry (Anorganic)  
6.2021 Professor of Medicine at Istinye University-VM Medical Park Hospital

## CERTIFICATES

Ethics course of experimental animals; Istanbul University Cerrahpasa School of Medicine Sep,2006.  
ECG course, Turkish Cardiology Association, Apr 2007.  
Good Clinical Practice, 2015,2017

### Phase Trials

My team is enrolling more than 20 phase 2 and 3 trials.

## EDUCATIONAL PROGRAMS ATTENDED

- III.Diabetic Endocrinology and Metabolism Course of Istanbul Faculty of Medicine, Istanbul Dec 11-14 th 2005.
- Turkish Internal Medicine Specialists Society Congress.Sep 13- 17th, 2006. Antalya,
- Traditional Internal Medicine Days, Interactive Update Symposium , Istanbul, Mar 09-11th 2007.

- Turkish Cardiology Association, Interactive Updates , Mar 31th –Apr 1st , 2007
- Turkish Internal Medicine Specialists Society Congress. Sep 5-9th 2007. Antalya

### INTERNATIONAL PUBLICATIONS

1. Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, Samantas E, Barlesi F, Roch B, Guillou A, Daurès JP. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. *PLoS One*. 2019 Aug 20;14(8):e0220988
2. Eskiler GG, Bezdegumeli E, Ozman Z, Ozkan AD, Bilir C, Kucukakca BN, Ince MN, Men AY, Aktas O, Horoz YE, Akpinar D, Genc I, Kaleli S. IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. *Bratisl Lek Listy*. 2019;66(11):819-826. doi: 10.4149/BLL\_2019\_136
3. Sarisozen C, Tan Y, Liu J, Bilir C, Shen L, Filipczak N, Porter TM, Torchilin VP. MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation. *J Drug Target*. 2019 Jan 25:1-10. doi: 10.1080/1061186X.2019.1570518
4. Guney Eskiler G, Deveci AO, Bilir C, Kaleli S. Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells. *Nutr Cancer*. 2019 Apr 30:1-14. doi: 10.1080/01635581.2019.1601237.
5. C Bilir, B Yusufoglu, B Kizilkaya, H Engin. Prognostic Value of Pre-and Posttreatment PET/CT Parameters in Patients Diagnosed with Advanced Stage NSCLC. *Current Medical Imaging Reviews* 2018. 14 (4), 621-628
6. Akdemir N, **Bilir C**, Yigin A.K, Yigin A, Bostanci MS, Yuvaci HU, Bilir F, Cevrioglu AS, Unal O and Ozden S. Labor Pain Intensity is Associated with HLA-B27 Seropositivity in Pregnant Women During Delivery. *Ciencica e Tecnica Vitivinicola*. Vol 32, 10,2017.-83-100. ISSN:0254-0223.
7. Demirtas D, **Bilir C**, Demirtas AO, Engin H. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer. *Clin Cases Miner Bone Metab*. 2017 Jan-Apr;14(1):35-39. doi: 10.11138/ccmbm/2017.14.1.035.
8. **Bilir C**, Durak S, Kizilkaya B, Hacibekiroglu I, Nayir E, Engin H. Efficacy of metronomic vinorelbine in

elderly patients with advanced non-small-cell lung cancer and poor performance status. *Curr Oncol.* 2017 Jun;24(3):e199-e204. doi: 10.3747/co.24.3486.

9. **Bilir C**, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Varım C, Cinemre H. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. *Cancer Invest.* 2017 Apr 21;35(4):248-255. doi: 10.1080/07357907.2017.1292518.
10. Aydın D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, **Bilir C**, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). *J BUON.* 2016 Sept-Oct;21(5):1242-1249.
11. Nayır E, Tanrıverdi O, Karakas Y, Kilickap S, Serdar Turhal N, Avcı N, Okutur K, Koca D, Erdem D, Abalı H, Yamac D, **Bilir C**, Kacan T. Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study. *J BUON.* 2016 May-Jun;21(3):714-9.
12. Yaylacı S, Ayyıldız O, Aydın E, Osken A, Karahalil F, Varım C, Demir MV, Genç AB, Sahinkus S, Can Y, Kocayigit I, **Bilir C**. Is there a difference in mad honey poisoning between geriatric and non-geriatric patient groups? *Eur Rev Med Pharmacol Sci.* 2015 Dec;19(23):4647-53.
13. **Bilir C**, H Engin, M Can, YB Temi, D Demirtas. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. *Medical Oncology*, February 2015, 32:56.
14. **Bilir C**, Engin H, and Temi YB. Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin. *Advances in Hematology*. Volume 2014 (2014), Article ID 473482, 5 pages.
15. Osman Zikrullah Sahin, **Cemil Bilir** and Teslime Ayaz. Colectomy and Acute Renal Failure: A Case Report with Unusual Presentation. *Case Reports in Nephrology*. Volume 2014 (2014), Article ID 821970, 3 pages.
16. **Bilir C**, Engin H, Can M, ilikhan S, Demirtas D, Kuzu F, Bayraktaroglu T. Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-

negative breast cancer. *Oncology Letters*, 2015. DOI: 10.3892/ol.2015.3094

17. **Bilir C**, Engin H, Karabag T, Colak D. Effects of folinic acid and fluorouracil chemotherapy on right ventricle functions as assessed with tricuspid annular plane systolic excursion. *Hippokratia* 2014, 18 (4):346-349.
18. U.Uyeturk, B.Oksuzoglu,T.Akman, I.Turker, N.Sener, D.Tastekin,O.Bal, V.Berk, U.Y.Arslan, Z.Urakci , C.Bilir, U.Yilmaz, D.Yazilitas, A.Ulas, O.U.Sonmez, B.Budakoglu,S.Cihan, M.Uysal. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology. *Med Oncol.* 2014 Apr;31(4):929. doi: 10.1007/s12032-014-0929-0.
19. Engin H, **Bilir C**, Tekin IO. Prognostic significance of peripheral blood flow cytometry parameters in patients with non-metastatic breast cancer. *Asian Pac J Cancer Prev.* 2013;14(12):7645-9.
20. **Bilir C**, Engin H. Amiodarone and the risk of cancer: a nationwide population-based study. *Cancer.* 2013 Oct 1;119(19):3578
21. Bilir F, Akdemir N, Ozden S, Cevrioglu AS, **Bilir C**. Increased serum procalcitonin levels in pregnant patients with asymptomatic bacteriuria. *Ann Clin Microbiol Antimicrob.* 2013 Sep 5;12:25.
22. **Bilir C**, Engin H, Bakkal BH, İlikhan SU, Malkoç D. Chemotherapy in elderly patients with metastatic gastric cancer; A single Turkish cancer center experience. *Medicinski Glasnik.* Epub, 2013.
23. Akdemir N, Cevrioglu AS, Ozden S, Kuru B, Bilir F, **Bilir C**. Platelet Indices and Blood Groups in Early Recurrent Miscarriage: A Study in Pregnant Women. *J Clin Gynecol Obstet.* Epub, 2013
24. **Bilir C**, Engin H, Temi YB, Toka B, Karabağ T. Acute myocardial infarction caused by filgrastim: a case report. *Case Rep Oncol Med.* 2012;2012:784128. doi: 10.1155/2012/784128. Epub 2012 Dec 23.
25. Engin H, **Bilir C**, Ustündağ Y. MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. *Support Care Cancer.* 2012 Oct 27. [Epub ahead of print]
26. **Bilir C**, Engin H, Üstün H, Üstündağ Y. Gemcitabine-Cisplatin Induced Acute Pancreatitis: a Case Report. *HealthMED - Volume 6 / Number 5 / 2012.*
27. Engin H, **Bilir C**, Üstün H, Gökmen A. ABO blood group and risk of pancreatic cancer in a Turkish

population in Western Blacksea region. *Asian Pac J Cancer Prev.* 2012;13(1):131-3.

28. Akdemir N, Akarsu S, Türe S, Ozlem Akcinar V, Yalcin AA, **Bilir C**, Serhan Cevrioglu A, Ozden S, Yucel M, Yurumez Y. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of maternal cardiac ischemia in low risk obstetric population during delivery. *Med Glas Ljek komore Zenicko-doboj kantona.* 2012 Aug;9(2):256-61.
29. **Bilir C**, Gökosmanoglu F, Caliskan M, Cinemre H, Akdemir R. Regression of the carotid intima media thickness by propylthiouracil therapy in Graves' hyperthyroidism. *Am J Med Sci.* 2012 Apr;343(4):273-6.
30. **Bilir C**, Akdemir N, Colak D, Cinemre H. Electrocardiographic findings in patients with primary dysmenorrhea. *Am J Med Sci.* 2012 Jan;343(1):27-9.
31. **Bilir C**, Akarsu S, Akdemir N, Gokosmanoglu F. Increased Cys-C Levels in Hyperemesis Gravidarum. *Journal of Clinical Gynecology and Obstetrics.* 1:1; 2012
32. Akdemir N, Cinemre H, **Bilir C**, Akin O, Akdemir R. Increased serum asymmetric dimethylarginine levels in primary dysmenorrhea. *Gynecol Obstet Invest.* 2010;69(3):153-6.
33. Cinemre H, **Bilir C**, Akdemir N. Isolated renal vein thrombosis associated with MTHFR-1298 and PAI-1 4G gene mutations. *Clin Appl Thromb Hemost.* 2010 Dec;16(6):708-10.
34. Cinemre H, **Bilir C**, Gokosmanoglu F, Akdemir N, Erdogmus B, Buyukkaya R. Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil. *Clin Invest Med.* 2009 Jun 1;32(3):E199-205.
35. Cinemre H, **Bilir C**, Gokosmanoglu F, Bahcebasi T. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study. *J Clin Endocrinol Metab.* 2009 Jan;94(1):151-6.
36. Cinemre H, **Bilir C**, Gokosmanoglu F, Kadakal F. Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction. *J Investig Med.* 2007 Dec;55(8):444-9.
37. Akdemir R, Yildiz A, Bulur S, Kaya A, **Bilir C**, Uyan C. Deer horn image in the liver associated with giant right atrium. *Am J Geriatr Cardiol.* 2007 May-Jun;16(3):200-1.
38. Akdemir R, Duran S, Bulur S, Kaya A, Sozen SB, **Bilir C**, Arinc H, Uyan C. A closed interatrial septal

aneurysm mimicking a tumor in the left atrium. Tex Heart Inst J. 2006;33(3):410-1.

39. Yildiz A, Biçeroglu S, Yakut N, **Bilir C**, Akdemir R, Akilli A. Acute myocardial infarction in a young man caused by centipede sting. Emerg Med J. 2006 Apr;23(4):e30.

40. Duran S, Bulur S, Sozen SB, **Bilir C**, Uyan C, Akdemir R. Images in emergency medicine: Acute severe coronary spasm associated with 5-fluorouracil chemotherapy. Emerg Med J. 2006 Jan;23(1):85.

#### **Ongoing-Presubmission projects**

- 1- COVID 19 vaccination and efficacy of vaccines in cancer patients.
- 2- Hematologic parameters in gynecologic cancer.
- 3- PET CT patterns and relation with molecular alterations in cancer patients
- 4- IDO inhibitors and breast cancer cells (in vitro research)
- 5- I enrolled 3 BAP and TÜBİTAK project which are ongoing.